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Purpose: Non-alcoholic fatty liver disease (NAFLD) ranges from simple steatosis to non-alcoholic steatohepatitis
(NASH). NASH, which is accompanied by increased oxidative stress and inflammation in the liver, is associated with
hepatic carcinogenesis. Green tea catechins (GTCs) possess anti-oxidant, anti-inflammatory, and cancer-preventive
properties. In this study, we investigated whether (−)-epigallocatechin-3-gallate (EGCG), a major component of GTCs,
inhibits NAFLD/NASH-related liver tumorigenesis.
Methods: Male 8-week-old Sprague–Dawley (SD) rats were administered a single intraperitoneal injection of a
hepatic carcinogen diethylnitrosamine (DEN, 30 mg/kg body weight) and then fed a high-fat diet (HFD) for 7 weeks.
The rats were also provided tap water containing 0.01% or 0.1% EGCG during the experiment.
Results: At sacrifice, the livers of SD rats treated with DEN and HFD exhibited marked development of glutathione
S-transferase placental form (GST-P)-positive foci, a hepatic preneoplastic lesion, and this was associated with
hepatic steatosis, oxidative stress and inflammation, and hepatocyte proliferation. EGCG administration, however,
inhibited the development of GST-P-positive foci by decreasing hepatic triglyceride content, reducing hepatic
fibrosis, lowering oxidative stress, attenuating inflammation, and inhibiting excessive hepatocyte proliferation in
DEN- and HFD-treated SD rats. These findings suggest that the experimental model of SD rats treated with HFD
and DEN, in which histopathological and pathophysiological characteristics of NASH and the development of
hepatic premalignant lesions were observed, might facilitate the evaluation of liver tumorigenesis associated with
NAFLD/NASH.
Conclusions: Administering EGCG, a GTC, might serve as an effective chemoprevention modality for
NAFLD/NASH-related liver tumorigenesis.
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Non-alcoholic fatty liver disease (NAFLD), which is con-
sidered a hepatic manifestation of the metabolic syn-
drome, is currently one of the most common chronic liver
diseases worldwide. NAFLD is classified into simple
steatosis and non-alcoholic steatohepatitis (NASH), the
latter being a severe condition of inflamed fatty liver* Correspondence: shimim-gif@umin.ac.jp
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in any medium, provided the original work is pthat can, in time, lead to hepatic fibrosis, cirrhosis, he-
patocellular carcinoma (HCC) development, and result
in increased mortality (Chiang et al., 2011; Cusi, 2012;
Siegel and Zhu, 2009). Steatohepatitis has been indi-
cated by epidemiological studies to be a significant risk
factor for developing HCC, at an annual HCC incidence
of 2%–3% in patients with NASH (Adams et al., 2005;
Ascha et al., 2010). In 1998, Day and James proposed a
“two-hit theory” to explain NAFLD/NASH pathogenesis:
the first hit, hepatic steatosis, increases the sensitivity of
the liver to proinflammatory insults, while the second hit
involves oxidative stress (Day and James, 1998). OxidativeOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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et al., 2013), is substantially higher in NASH patients than
in NAFLD patients and normal control subjects (Sanyal
et al., 2001). Moreover, tumor necrosis factor (TNF)-α and
interleukin (IL)-6, both of which are major proinflam-
matory cytokines, play a critical role in obesity-related
steatohepatitis and subsequent liver tumorigenesis (Park
et al., 2010).
Several animal models that mimic the pathophysiological
mechanisms associated with NAFLD/NASH-related liver
carcinogenesis have been developed recently (Hebbard
and George, 2011; Schattenberg and Galle, 2010; Kochi
et al., 2013). For instance, db/db mice, which exhibit
obesity, diabetes, dyslipidemia, and severe steatosis, are
susceptible to liver tumorigenesis induced by a hepatic
carcinogen diethylnitrosamine (DEN), and thus are re-
garded as useful animal models for investigating patho-
biology of NAFLD/NASH-related liver carcinogenesis
and for screening the chemopreventive effects of vari-
ous compounds either synthetic or natural on NAFLD/
NASH-related liver carcinogenesis (Iwasa et al., 2010;
Shimizu et al. 2011a, 2011b, 2011c). Recently, Wang
et al. (Wang et al. 2009) reported that NASH induced
by a high-fat diet (HFD) promoted DEN-initiated early
hepatocarcinogenesis in Sprague–Dawley (SD) rats and
that this was associated with increased oxidative stress
and inflammation. This animal model is also useful for
investigating the efficacy of certain types of synthetic
compounds and/or phytochemicals in preventing NASH-
promoted liver carcinogenesis (Wang et al., 2010).
The prevalence of NAFLD/NASH has risen recently in
parallel with the dramatic increase in obesity and its re-
lated metabolic abnormalities, especially diabetes mellitus
(Chiang et al., 2011; Cusi, 2012; Siegel and Zhu, 2009), in-
dicating an urgent requirement for developing an effective
strategy to treat NAFLD/NASH and, consequently, to pre-
vent NAFLD/NASH-related liver carcinogenesis. A recent
randomized trial (Sanyal et al., 2010) has shown that treat-
ment with vitamin E, an antioxidant, reduces steatosis
and lobular inflammation in the liver of NASH patients.
Reducing oxidative stress and inhibiting the inflammation
induced by obesity and steatosis are also effective in pre-
venting obesity- and diabetes-related hepatotumorigenesis
(Shimizu et al. 2013, 2012). These reports suggest that
targeting oxidative stress and chronic inflammation isTable 1 Body and organ weights of the experimental rats
Group No. EGCG No. of rats Bodyweight (g
1 - 7 512.7 ± 37.
2 0.01% 6 495.5 ± 29
3 0.1% 6 501.6 ± 44
aMean ± SD.an optimal strategy for preventing NAFLD/NASH-related
liver carcinogenesis.
Green tea catechins (GTCs) might be one of the most
promising candidate compounds for preventing NAFLD/
NASH-related liver carcinogenesis because they are con-
sidered to protect against metabolic disorders such as
NAFLD (Masterjohn and Bruno, 2012; Thielecke and
Boschmann, 2009) and also display cancer chemopre-
ventive properties in various tissues, including the liver
(Shimizu et al. 2011b; Kochi et al., 2013; Yang et al.,
2009). In this study, we developed a novel rat model of
NAFLD/NASH-related carcinogenesis and investigated
the potential capacity of (−)-epigallocatechin-3-gallate
(EGCG), a major component of GTCs, to inhibit the
occurrence of HFD- and DEN-induced glutathione S-
transferase placental form (GST-P)-positive foci, an indi-
cator of preneoplastic HCC lesions in rats (Tsuda et al.,
2003; Ando et al., 2007).
Results
General observations
At the end of the experimental period, the rats in the 3
groups exhibited no significant differences with respect
to the mean body, liver, and kidney weights (Table 1).
Histopathological examination revealed that administering
EGCG produced no detectable toxic effects on critical
organs including the liver, kidney, and spleen (data not
shown).
Effects of EGCG on hepatic steatosis and serum ALT levels
in rats
At sacrifice, macrovesicular steatosis with ballooned hepa-
tocytes, Mallory-Denk bodies, and foci of inflammatory
cells, which are a recognized feature of NASH (Kleiner
et al., 2005), were observed in the livers of rats in all groups,
indicating that the histopathological characteristics that de-
velop in this animal model reproduce those of NASH.
However, these pathological effects were alleviated by the
administration of 0.01% and 0.1% EGCG (Figure 1a and
1b). In particular the total NAFLD activity score (NAS)
consisting of the steatosis, inflammation, and ballooning
scores, was significantly lower in 0.1% EGCG-treated rats
than in EGCG-untreated control rats (Figure 1c, P < 0.05).
Similar results were obtained following measurement of
intrahepatic lipid content: the levels of liver triglycerides in)
Relative organ weight (g/100 g body weight)
Liver Kidneys
8a 3.8 ± 0.5 0.6 ± 0.4
.0 3.9 ± 0.6 0.7 ± 0.3
.3 3.5 ± 0.2 0.6 ± 0.3
Figure 1 Hepatic histopathology, intrahepatic levels of triglycerides, and serum levels of ALT. (a) and (b) H&E staining of liver sections
from the experimental rats. (a) Representative photomicrographs of liver sections of rats treated DEN/HFD with or without EGCG. Bars, 100 μm.
(b) An enlarged photo of the liver section from a rat treated DEN/HFD without EGCG (an enclosed area with square in Figure 1a). Note ballooned
hepatocytes (indicated by the white arrow), Mallory-Denk bodies (indicated by the black arrow), and focus of inflammatory cells (circled by dotted
line). Bars, 50 μm. (c) The NAS was determined from histopathological analysis. (d) Hepatic lipids were extracted from frozen liver samples of rats
in the 3 groups, and the triglyceride (TG) levels were measured. (e) Blood samples were collected at sacrifice and the serum levels of alanine
aminotransferase (ALT) were determined. The values are expressed as mean ± SD. *P < 0.05. Ctrl, control group.
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creased when they received 0.01% and 0.1% EGCG instead
of water (Figure 1d, P < 0.05). The serum alanine amino-
transferase (ALT) levels were also significantly decreased
with EGCG treatment at both concentrations relative to
the levels in the water-treated group (Figure 1e, P < 0.05),
indicating that EGCG protected against hepatic steatosis
and subsequent hepatocyte injury induced by DEN and
HFD.Effects of EGCG on liver fibrosis in rats
Examination of Azan-stained liver sections revealed that
DEN- and HFD-treated SD rats developed perisinusoidal
fibrosis, but that EGCG administration reduced liver fi-
brosis in the animals (Figure 2a). The liver fibrosis score
was also significantly decreased by EGCG administration
(Figure 2b). Furthermore, EGCG treatment significantly
lowered (relative to control) the hepatic levels of TIMP-1
and TIMP-2 mRNA in the DEN- and HFD-treated SD
rats (Figure 2c, P < 0.05).Effects of EGCG on the development of hepatic
preneoplastic lesions in rats
At the end of the experiment, GST-P-positive foci were
detected in the livers of the rats, all of which had received
DEN/HFD (Figure 3a). However, compared with rats in
the control group that were not treated with EGCG, rats
treated with EGCG showed a significant reduction in the
number of GST-P-positive foci: 86% and 87% reductionrelative to control following treatment with 0.01% and
0.1% EGCG, respectively (Figure 3b, P < 0.01).
Effects of EGCG on oxidative stress in rats
Oxidative stress plays a critical role in the NAFLD-to-
NASH progression and HCC development (Chiang et al.,
2011; Cusi, 2012; Siegel and Zhu, 2009). Therefore, we
examined the levels of oxidative stress and antioxidant
biomarkers in the experimental rats. Rats administrated
with 0.1% EGCG had significantly reduced levels of
urinary 8-OHdG, a marker of DNA damage induced by
oxidative stress, compared with EGCG-untreated con-
trol rats (Figure 4a, P < 0.01). The serum d-ROM level,
which reflects serum hydroperoxide levels, was also de-
creased relative to control in rats treated with 0.01%
and 0.1% EGCG (Figure 4b, P < 0.01). Moreover, the
antioxidant enzyme (catalase and GPx-1) levels were
significantly increased in the livers of rats that received
EGCG treatment (Figure 4c, P < 0.05). These results indi-
cate that drinking EGCG attenuated both systemic and
hepatic oxidative stress in our rat model of NAFLD/
NASH-related liver tumorigenesis.Effects of EGCG on hepatic expression of TNF-α, IL-6, and
IL-1β mRNA in rats
Chronic inflammation is implicated in the progression of
NASH and subsequent liver carcinogenesis (Chiang et al.,
2011; Cusi, 2012; Siegel and Zhu, 2009; Park et al., 2010).
Therefore, the mRNA expression levels of 3 inflammatory
Figure 2 Liver fibrosis and hepatic expression levels of TIMP-1 and TIMP-2 mRNA. (a) Representative photomicrographs of Azan staining of
liver tissues to show fibrosis. Bars, 50 μm. Note reduction of liver fibrosis (blue) by the treatment with EGCG. (b) Liver fibrosis evaluation was
based on the NAS system. (c) After total RNA was isolated from the livers of the rats, the levels of TIMP-1 and TIMP-2 mRNA were measured using
specific primers and quantitative real-time RT-PCR. The values are expressed as mean ± SD. * P < 0.05.
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livers of DEN- and HFD-treated SD rats. As shown in
Figure 5, quantitative real-time RT-PCR analysis revealed
that rats that received 0.1% EGCG exhibited significantly
lower hepatic levels of TNF-α (P < 0.05), IL-6 (P < 0.01),
and IL-1β (P < 0.05) mRNA than control rats that received
only water, and the hepatic levels of IL-6 mRNA were also
decreased by the administration of a low dose (0.01%) of
EGCG (P < 0.01).Figure 3 The development of GST-P-positive foci in the livers. (a) Rep
GST-P focus in a rat treated with DEN/HFD. Bars, 50 μm. (b) The average nu
groups. The values are expressed as mean ± SD. # P < 0.01.Effects of EGCG on hepatocyte proliferation and hepatic
expression of cyclin D1 mRNA in rats
The PCNA-labeling index of non-lesional hepatocytes in
DEN- and HFD-treated SD rats was determined based
on the findings of immunohistochemical examination of
sections (Figure 6a). The mean PCNA-labeling indices
measured for rats administered 0.01% and 0.1% EGCG
were significantly lower than that for EGCG-untreated
control rats (Figure 6b, P < 0.01). Furthermore, the levelsresentative photomicrographs of GST-P-positive foci. Note a large
mbers of GST-P-positive foci formed in the livers of the rats in the 3
Figure 4 Urinary 8-OHdG and serum d-ROM levels and on the hepatic catalase and GPx-1 mRNA levels. (a) The urinary 8-OHdG levels
were measured using ELISA. (b) Hydroperoxide levels in the serum were determined using the d-ROM test. (c) Levels of catalase and GPx-1 mRNA
in the livers of the experimental rats were measured using specific primers and quantitative real-time RT-PCR. The values are expressed as mean ± SD.
#P <0.01, *P <0.05.
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creased in EGCG-treated rats relative to that in control
rats (Figure 6c, P < 0.05), indicating that EGCG signifi-
cantly inhibited hepatocyte proliferation in DEN- and
HFD-treated SD rats.
Discussion
An increase in the prevalence of NAFLD/NASH, which
can progress to HCC, is a major healthcare problem
worldwide (Chiang et al., 2011; Cusi, 2012; Siegel and
Zhu, 2009). Therefore, developing an effective strategy
for preventing NAFLD/NASH-related liver tumorigenesis
is critical for improving the prognosis of patients with
these diseases. The results of this study clearly indicate
that EGCG, a GTC, effectively prevents the development
of hepatic preneoplastic lesions, which manifest as GST-Figure 5 Hepatic expression of TNF-α, IL-6, and IL-1β mRNA. Total RNA
expression levels of TNF-α, IL-6, and IL-1β mRNA were determined using sp
expressed as mean ± SD. # P <0.01, *P <0.05.P-positive foci, in our rat model of NAFLD/NASH-related
liver tumorigenesis. The rodent model used in this study,
which was modified from a model described previously
(Wang et al., 2009), reflects the pathological alterations
implicated in NAFLD/NASH and NAFLD/NASH-related
liver tumorigenesis, including the induction of oxidative
stress and chronic inflammation (Chiang et al., 2011; Cusi,
2012; Siegel and Zhu, 2009; Park et al., 2010). Therefore,
we consider the present model to be an appropriate and a
useful animal model for analyzing the mechanisms of
NAFLD/NASH-related liver tumorigenesis and for evalu-
ating the efficacy of specific chemopreventive agents that
can suppress such tumorigenesis.
Among the numerous pathophysiological conditions as-
sociated with NAFLD/NASH, oxidative stress is regarded
as one of the key mechanisms for the development ofwas isolated from the livers of rats in the 3 groups and the
ecific primers and quantitative real-time RT-PCR. The values are
Figure 6 Hepatocyte proliferation and hepatic expression of cyclin D1 mRNA. (a) Immunohistochemical labeling for PCNA in the livers of
the experimental rats. Bars, 100 μm. (b) The PCNA-labeling index in non-lesional hepatocytes was determined by counting the hepatocytes with
PCNA-positive nuclei to calculate their percentage in the hepatocyte population. (c) The cyclin D1 mRNA levels in the liver of the experimental
rats were determined using specific primers and quantitative real-time RT-PCR. The values are expressed as mean ± SD. # P <0.01, *P <0.05.
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in oxidative stress, which is defined as the overproduction
of reactive oxygen species combined with inadequate anti-
oxidative defense mechanisms, produces DNA damage
and gene mutations associated with liver carcinogenesis
(Chiang et al., 2011; Cusi, 2012; Siegel and Zhu, 2009; Park
et al., 2010). Conversely, treatment with antioxidants such
as vitamin E can reduce hepatic steatosis, lobular inflam-
mation, and serum ALT levels, as shown by a clinical trial
conducted in NASH patients (Sanyal et al., 2010). Admin-
istering pentoxifylline, which is known to decrease oxida-
tive stress and inhibit TNF-α expression, also improved
the histological features of NASH in a recent randomized
placebo-controlled trial (Zein et al., 2011). In this study,
treatment with EGCG lowered the levels of oxidative
stress-associated markers such as urinary 8-OHdG and
serum d-ROM, whereas elevated the mRNA levels of
two antioxidant enzymes, catalase and GPx-1, in the
liver of DEN- and HFD-treated SD rats. These findings
suggest that EGCG suppressed NAFLD/NASH-related
liver tumorigenesis at least partly by reducing systemic
and hepatic oxidative stress. Our results are consistent
with those of previous studies showing that GTCs can
protect against both oxidative stress and the progression
of NAFLD to NASH (Park et al., 2011; Ueno et al., 2009;
Kuzu et al., 2008).
Besides oxidative stress, chronic inflammation is critic-
ally involved in NAFLD/NASH-related liver tumorigenesis
(Chiang et al., 2011; Cusi 2012; Siegel and Zhu, 2009;
Park et al., 2010). Among the proinflammatory cytokinesrelated to the progression of NASH, TNF-α and IL-6 play
a pivotal role in hepatocyte injury and inflammation,
which increase HCC risk (Park et al., 2010). Therefore,
targeting TNF-α and IL-6 might be an effective method
to suppress NAFLD/NASH-related liver tumorigenesis.
GTCs are widely recognized to exert cancer-preventive
effects partly by inhibiting the expression of TNF-α and
IL-6 (Shimizu et al. 2011b; Kochi et al., 2013; Shirakami
et al. 2008), indicating that the suppression of inflam-
mation is one of the key mechanisms by which GTCs
prevent cancer development. In this study, we found
that mRNAs encoding TNF-α, IL-6, and IL-1β were
expressed at significantly lower levels in the livers of
EGCG-treated rats compared to that in EGCG-untreated
rats. Therefore, in agreement with previous reports
(Shimizu et al. 2011b; Kochi et al., 2013; Shirakami et al.
2008), the results of this study suggest that EGCG con-
sumption suppressed the development of GST-P-positive
foci in DEN- and HFD-treated SD rats by attenuating
chronic inflammation.
In addition to reducing oxidative stress and chronic
inflammation, both of which are secondary manifesta-
tions of NASH, administering EGCG improved hepatic
steatosis, a primary manifestation of NASH (Day and
James, 1998), decreased serum ALT levels, ameliorated
liver fibrosis, and inhibited excessive hepatocyte prolif-
eration in this study. GTCs have been demonstrated to
attenuate hepatic fat accumulation in several laboratory
animal studies (Kuzu et al., 2008; Kochi et al., 2013;
Shimizu et al. 2011b; Park et al., 2011; Ueno et al., 2009);
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of interest because hepatic steatosis per se can induce
hepatocyte proliferation and hepatic hyperplasia, both
of which initiate the hepatic neoplastic process by in-
creasing hepatocyte proliferative activity (Yang et al.,
2001). Moreover, hepatic steatosis is critically related to
liver fibrosis, which is a strong risk factor for the develop-
ment of HCC (Powell et al., 2005). Therefore, suppression
of hepatic steatosis and fibrosis by EGCG treatment might
help to inhibit the progression of NAFLD/NASH-related
liver tumorigenesis at an early stage.
Because GST-P-positive foci are generally accepted to
be precursors or preneoplastic lesions of HCC in rats
(Tsuda et al., 2003; Ando et al., 2007), the rodent model
used in this study appears to be well suited for screening
reagents that can prevent NAFLD/NASH-related liver
tumorigenesis. However, the current study has one limita-
tion that hepatocellular neoplasms, including HCC, did
not develop within the experimental period. Because the
duration of the experiment (7 weeks) might have been
insufficient for the development of hepatic neoplasms,
future studies should be conducted using longer-term
experiments to confirm that HFD- and DEN-treated SD
rats develop hepatocellular neoplasms.
Finally, we emphasize again that targeting metabolic
abnormalities, especially oxidative stress and chronic
inflammation, might be one of the most practical
approaches for treating NAFLD/NASH and preventing
NAFLD/NASH-related liver carcinogenesis (Shimizu
et al. 2013, 2012). We consider GTCs including EGCG
to be potentially effective and key candidates for this
purpose, because these agents can target metabolic ab-
normalities and thus prevent relevant tumorigenesis,
as shown by the results of this study and those from
previous reports (Shimizu et al. 2011b; Kochi et al.,
2013; Shimizu et al. 2008b; Thielecke and Boschmann,
2009; Grove and Lambert, 2010). Recent clinical trials
have also demonstrated that GTC supplementation po-
tently prevents the development of both colorectal aden-
omas and prostate cancers without causing adverse effects
(Shimizu et al. 2008a; Bettuzzi et al., 2006). These benefi-
cial effects of GTCs reported in clinical trials strongly en-
courage the clinical usage of GTCs for treating NAFLD/
NASH patients to prevent the metabolic abnormalities,
such as steatosis, hyperlipidemia, and hyperinsulinemia, as
well as liver carcinogenesis.
Conclusions
In conclusion, administering EGCG effectively suppresses
the early stage of hepatocarcinogenesis in our rat model
of NAFLD/NASH by attenuating oxidative stress and
chronic inflammation. Application of GTCs represents
a potential new strategy for preventing the development
of hepatic neoplasms in NAFLD/NASH patients.Methods
Animals and chemicals
Male 7-week-old SD rats were obtained from Japan SLC,
Inc. (Shizuoka, Japan) and humanely maintained at Gifu
University Life Science Research Center in accordance
with the Institutional Animal Care Guidelines. DEN was
purchased from Sigma-Aldrich Co. LLC. (St. Louis, MO,
USA). HFD-60 (HFD, 506.2 kcal/100 g) with 62.2% of the
calories derived from fat was purchased from Oriental
Yeast (Tokyo, Japan) (Table 2). EGCG was obtained from
Mitsui Norin Co. Ltd. (Tokyo, Japan).
Experimental procedure
The present study was approved by the Experimental
Animal Research Committee of Gifu University. After
1-week-acclimatization with regular chow, all rats (n = 19)
received a single intraperitoneal injection of DEN (30 mg/kg
body weight) and were then randomly divided into 3
groups. Following DEN injection, the rats in Groups
2 and 3 (n = 6 in both groups) were provided tap water
containing 0.01% or 0.1% EGCG, respectively, whereas
the rats in Group 1 (n = 7) were provided tap water
throughout the experiment, which lasted 7 weeks. All
rats were fed a pelleted HFD throughout the experiment
after DEN injection. At the end of the experiment, the
15-week-old rats were sacrificed by CO2 asphyxiation and
the development of GST-P-positive foci was evaluated. The
concentration of EGCG used (0.1%), which was established
based on the findings of previous chemopreventive studies
Table 3 Primer sequences
Target gene Direction Primer sequences (5′-3′)
Catalase Forward GCGAATGGAGAGGCAGTGTAC
Reverse GAGTGACGTTGTCTTCATTAGCACTG
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2008; 2009), was, in terms of units per body weight,
within the physiological range measured in humans
after daily intake of GTCs (Wang et al., 1991). Previously,
GST-P-positive foci were markedly induced by DEN
injection in HFD fed rats, but not in rats fed a normal diet
(Wang et al. 2009), therefore we did not use a control
group that was fed normal chow diet after DEN injection
in the present study.
Histopathological examination and immunohistochemical
analyses for GST-P and proliferating cell nuclear
antigen (PCNA)
Maximum sagittal sections of 3 liver sublobes (central, lat-
eral, and right-anterior) were used for histopathological
examination. Formalin-fixed and paraffin-embedded livers
were stained with hematoxylin & eosin (H&E) for con-
ventional histopathology or with Azan stain to detect
liver fibrosis. The histological features of the livers were
evaluated using the NAFLD activity score (NAS) system
(Kleiner et al., 2005), and the development of liver fibro-
sis was determined as described previously (Kleiner
et al., 2005). Immunohistochemistry for GST-P (Ando
et al., 2007) and PCNA (Iwasa et al., 2010) was performed
using primary antibodies against GST-P (MBL Co. Ltd.,
Nagoya, Japan) and PCNA (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), respectively. The number of
GST-P-positive foci, which was set as 3 or more positive
cells (Kochi et al., 2013), was assessed per unit area (per
cm2). In the PCNA-immunostained sections, cells with
intensely stained nuclei were considered to be positive
for PCNA, and the indices (% PCNA-positive) were
determined by counting at least 500 hepatocytes in each
section (total of 3000 hepatocytes per rat) (Iwasa et al.,
2010).
RNA extraction and quantitative real-time RT-PCR analysis
Total RNA was isolated from the livers of the rats by
using RNeasy Mini kit (QIAGEN, Venlo, Netherlands)
with on-column DNase I-digestion (Terakura et al., 2012).
From 0.2 μg of total RNA, cDNAs were amplified using
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Santa Clara, CA, USA) and an automated
thermal cycler (Bio-Rad Laboratories, Hercules, CA,
USA). Quantitative real-time reverse transcription-PCR
(RT-PCR) analysis was performed using specific primers
that amplify the TNF-α, IL-1β, IL-6, tissue inhibitor of
metalloproteinases (TIMP)-1, TIMP-2, glutathione perox-
idase (GPx)-1, catalase, cyclin D1, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) genes. The sequences
of these primers, which were obtained using Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/),
are shown in Table 3. Each sample was analyzed on
a LightCycler Nano (Roche Diagnostics, Mannheim,Germany) with FastStart Essential DNA Green Master
(Roche Diagnostics). GAPDH amplified in parallel served
as the internal control.
Clinical chemistry
At sacrifice, the serum levels of ALT were measured
using a standard clinical automatic analyzer (Type 7180;
Hitachi, Tokyo, Japan).
Hepatic lipid analysis
Total lipids were extracted from approximately 200 mg
of liver tissue (frozen at sacrifice) for each rat, and the
triglyceride levels were measured using the triglyceride
E-test kit (Wako, Osaka, Japan) (Iwasa et al., 2010).
Oxidative stress analysis
Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels
were determined using an ELISA kit (NIKKEN SEIL,
Shizuoka, Japan). Serum levels of hydroperoxide, one of
the markers for oxidative stress, were determined using
the derivatives of reactive oxygen metabolites (d-ROM)
test (FREE Carpe Diem; Diacron s.r.l., Grosseto, Italy)
(Kochi et al., 2013).
Statistical analysis
All data are expressed as mean ± SD, and one-way analysis
of variance (ANOVA) was used for comparisons between
groups. If ANOVA indicated significant differences, the
Tukey-Kramer test for multiple comparisons was per-
formed to compare the mean values among the groups.
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two-sided P value was less than 0.05. All analyses were
conducted by the GraphPad InStat software, Version
3.05 (GraphPad Software; San Diego, CA, USA).
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